Meiji Yasuda Asset Management Co Ltd. purchased a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 61,840 shares of the company’s stock, valued at approximately $7,946,000.
Several other institutional investors also recently bought and sold shares of the business. Frazier Financial Advisors LLC acquired a new position in shares of Merck KGaA during the 2nd quarter worth approximately $25,000. Rakuten Securities Inc. purchased a new stake in Merck KGaA in the 2nd quarter worth $27,000. Burk Holdings LLC acquired a new position in Merck KGaA during the second quarter worth $39,000. Bard Associates Inc. purchased a new position in Merck KGaA during the second quarter valued at $60,000. Finally, Kilter Group LLC purchased a new position in Merck KGaA during the second quarter valued at $62,000. 0.10% of the stock is owned by institutional investors and hedge funds.
Merck KGaA Price Performance
Shares of OTCMKTS MKGAF opened at $163.21 on Monday. The firm has a market cap of $21.09 billion, a price-to-earnings ratio of 24.92 and a beta of 0.96. The company’s 50-day simple moving average is $162.62 and its 200-day simple moving average is $148.44. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. Merck KGaA has a 52-week low of $116.68 and a 52-week high of $175.56.
Merck KGaA Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Read More
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
